Publications

Featured Papers
 
Povoski SP, Hatzaras IS, Mojzisik CM, Martin EW Jr. Oncologic Theranostics: Recognition of this Concept in Antigen-Directed Cancer Therapy for Colorectal Cancer with Anti-TAG-72 Monoclonal Antibodies. Expert Rev Mol Diagn. 2011;11(7):667-670.

[expand title=”Click for Summary”] “…the absence of detectable TAG-72 antigen within the surgical field at the completion of antigen-directed cancer surgery was of significant prognostic value, rendering TAG-72-negative patients a long-term and sustainable survival advantage over that of TAG-72-positive patients.”

“Antigen-directed cancer surgery using radiolabeled anti-TAG-72 monoclonal antibodies is a form of targeted cancer therapy and, more specifically, a form of antigen-directed cancer therapy.”

“The future direction for antigen-directed cancer therapy with anti-TAG-72 monoclonal antibodies is to expand this concept to a multimodality approach that encompasses … antigen-directed cancer imaging and a wide variety of potential adjuvant antigen-directed/targeted cancer therapies.”[/expand]

 

Povoski SP, Hatzaras IS, Mojzisik CM, Arnold MW, Hinkle GH, Hitchcock CL, Young DC, Martin EW Jr. Antigen-Directed Cancer Surgery for Primary Colorectal Cancer: 15-Year Survival Analysis. Ann Surg Oncol. 2011 Jul 6. [Epub ahead of print].

[expand title=”Click for Abstract”] Background

Tumor-associated glycoprotein-72 (TAG-72) is a mucin-like high-molecular-weight glycosylated protein complex overexpressed by many adenocarcinomas. Antigen- directed cancer surgery using radiolabeled anti-TAG- 72 murine monoclonal antibodies (muMAbs) has been previously investigated for colorectal cancer. Survival analysis of primary colorectal cancer patients with a minimum of 15-year follow-up after antigen-directed cancer surgery was performed to assess the impact of complete surgical resection of all detectable radiolabeled anti- TAG-72 muMAb.

Methods

Survival analysis was performed on 92 patients (study group) with primary colorectal cancer (July 1990 to August 1995) treated with antigen-directed cancer surgery using 125I-labeled anti-TAG-72 muMAb. The study group was subdivided into those with no detectable TAG-72 antigen-bearing tissues (TAG-72 negative, N = 33) and those with persistent detectable TAG-72 antigen-bearing tissues (TAG-72 positive, N = 59) at completion of surgery. Comparisons were made with a control group (546 patients) from the same time period.

Results

Study group and control group were demographically similar, as were TAG-72-negative subgroup and TAG-72-positive subgroup. TAG-72-negative subgroup had significantly improved median survival (8.8 versus 2.5 years; P = 0.005) and time-dependent survival (45.4% versus 22.0% at 10 years; P = 0.002 and 39.4% versus 20.3% at 15 years; P = 0.003) compared with TAG-72- positive subgroup. TAG-72 positivity was as an independent predictor of long-term mortality risk, when controlled for pathologic stage of disease.

Conclusions

Absence of detectable TAG-72 antigen within the surgical field at completion of antigen-directed cancer surgery for primary colorectal cancer is of significant prognostic value, conferring a long-term survival advantage to those in whom complete surgical removal of all tissues with detectable radiolabeled anti-TAG-72 muMAb was accomplished.[/expand]

 

Archived Papers
3E8

[expand title=”Click to Expand”]Kim SJ, Hong HJ. Guided selection of human antibody light chains against TAG-72 using a phage display chain shuffling approach. J Microbiol 2007;45:572-577.

Yoon SO, Lee TS, Kim SJ, Jang MH, Kang YJ, Park JH, Kim KS, Lee HS, Ryu CJ, Gonzales NR, Kashmiri SV, Lim SM, Choi CW, Hong HJ. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J Biol Chem 2006; 281:6985-6992.[/expand]
 

HuCC49DeltaCH2

[expand title=”Click to Expand”]Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mojzisik CM, Johnson MA, Knopp MV, Martin EW, Sun D. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: Preliminary results. World J Surg Oncol 2010;8:65.

Xu JS, Huang J, Qin R, Hinkle GH, Povoski SP, Martin EW, Xu RX. Synthesizing and binding dual-mode poly (lactic-co-glycolic acid) (PLGA) nanobubbles for cancer targeting and imaging. Biomaterials 2010;31:1716-1722.

Yu Y, Fang L, Sun D. Biodistribution of HuCC49∆CH2-β-galactosidase in colorectal cancer xenograft model. Int J Pharm 2010;386:208-215.

Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW Jr, Subramaniam V, Xu R, Sun D. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 2009;6:428-440.

Fang L, Sun D. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. Drug Metab Dispos 2008;36:1153-1165.

Cheng KT. 111In-(1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaaetic acid)-anti–TAG-72 humanized CH2 domain-deleted antibody. Molecular Imaging and Contrast Agent Database [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010. 2007 Aug 17 [updated 2008 Feb 12].

Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW Jr, Sun D. Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 2007;47:227-237.

Cheng KT. Radioiodinated anti-TAG-72 humanized CH2 domain-deleted antibody. Molecular Imaging and Contrast Agent Database [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010. 2007 Aug 30 [updated 2007 Nov 14].

Fang L, Battisti RF, Cheng H, Reigan P, Xin Y, Shen J, Ross D, Chan KK, Martin EW Jr, Wang PG, Sun D. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J Med Chem 2006;49:6290-6297.

Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G. Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother Radiopharm 2006;21:106-116.

Xiao J, Horst S, Hinkle G, Cao X, Kocak E, Fang J, Young D, Khazaeli M, Agnese D, Sun D, Martin E Jr. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm 2005;20:16-26.

Larson SB, Day JS, Glaser S, Braslawsky G, McPherson A. The structure of an antitumor C(H)2-domain-deleted humanized antibody. J Mol Biol 2005;348:1177-1190.

Glaser SM, Hughes IE, Hopp JR, Hathaway K, Perret D, Reff ME. Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies. J Biol Chem 2005;280:41494-41503.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother Radiopharm 2005; 20:502-513.

Agnese DM, Abdessalam SF, Burak WE, Arnold MW, Soble D, Hinkle GH, Young D, Kazaeli MB, Martin EW Jr. Pilot study using a humanized CC49 monoclonal antibody (HuCC49∆CH2) to localize recurrent colorectal carcinoma. Ann Surg Oncol 2004;11:197-202.

Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003;18:751-759.

Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol Immunol 2003;40:337-349.

De Pascalis R, Gonzales NR, Padlan EA, Schuck P, Batra SK, Schlom J, Kashmiri SV. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. Clin Cancer Res 2003;9:5521-5531.

Kashmiri SV, Iwahashi M, Tamura M, Padlan EA, Milenic DE, Schlom J. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Crit Rev Oncol Hematol 2001;38:3-16.

Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 1997;12:305-316.

Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 1995;14:461-473.

Slavin-Chiorini DC, Kashmiri SV, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, Hand PH. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;55(23 Suppl):5957s-5967s.

Slavin-Chiorini DC, Horan Hand PH, Kashmiri SV, Calvo B, Zaremba S, Schlom J. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int J Cancer 1993;53:97-103.

Calvo B, Kashmiri SV, Hutzell P, Hand PH, Slavin-Chiorini DC, Schlom J, Zaremba S. Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody. Cancer Biother 1993;8:95-109.[/expand]
 

Characterization and expression of TAG-72 antigen

[expand title=”Click to Expand”]Ouyang M, Wu W, Zou Y, Zhou J, Wang Z, Wan X. Immunoreactivity and prognostic value of tumor-associated glycoprotein 72 in primary gallbladder carcinoma. Surg Oncol 2009;May 14.[Epub ahead of print].

Wang SM, Mao J, Li B, Tang LL. [Clinical significance of tumor associated glycoprotein-72 expression in primary breast carcinoma.] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2008;24:1084-1086. [Chinese].

Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, Jain M, Smith L, Davis JS, Remmenga SW, Batra SK. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett 2007;251:247-257.

Maida Y, Kyo S, Inoue M. [CA72-4 (TAG-72)]. Nippon Rinsho 2005;63(Suppl 8):672-674. [Japanese].

Chhieng DC, Rodriguez-Burford C, Talley LI, Sviglin H, Stockard CR, Kleinberg MJ, Barnes MN, Partridge EE, Khazaeli MB, Grizzle WE. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol 2003;34:1016-1021.

Galietta A, Pizzi C, Pettinato G, Limite G, Sgambato A, Lamberti M, Muraro R, Formisano C, Pensabene M, Bianco AR, Mariani-Costantini R, Contegiacomo A. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype. Oncol Rep 2002;9:135-140.

Karan D, Johansson SL, Lin MF, Batra SK. Expression of tumor-associated glycoprotein-72 (TAG-72) antigen in human prostatic adenocarcinomas. Oncol Rep 2001;8:1123-1126.

González Vitores AM, Duró GE, Fraile BB, Carrasco MA. Prognostic value of the glycoprotein TAG-72 in patients with gastric cancer. Int J Biol Markers 2001;16:121-125.

Allende MT, Vizoso F, Suárez C, García I, Sanz L, García-Muñiz JL, Roiz C. TAG-72 in gastric cancer: relationship between preoperative serum levels and tumoral content of the antigen. Int J Biol Markers 2000;15:197-199.

Epivatianos A, Poulopoulos A, Kayavis I, Papanayotou P. Tumor-associated glycoprotein 72 (TAG-72) expression in salivary gland neoplasia: an immunohistochemical study using the monoclonal antibody (MAb) CC49. Oral Dis 2000;6:112-117.

Kanthan R, Xiang J, Magliocco AM. p53, ErbB2, and TAG-72 expression in the spectrum of ductal carcinoma in situ of the breast classified by the Van Nuys system. Arch Pathol Lab Med 2000;124:234-239.

Peláez Buján Mdel C, Ruibal Morell A, Aza González J. Gastric carcinoma: expression of c-erbB-2/neu oncoprotein, epidermal growth factor receptor, cathepsin D, progesterone receptor and tumor associated glycoprotein-72 in different histological types. Rev Esp Enferm Dig 1999;91:826-837.

Pizzi C, Sgambato A, De Laurentiis M, Limite G, Panico L, Pettinato G, Muraro R, Tauchmanova L, Galietta A, Bianco AR, Mariani-Costantini R, Contegiacomo A. TAG-72 expression and clinical outcome in primary breast cancer. Oncol Rep 1999;6:1399-1403.

Fernández-Llamazares J, Piñol M, Encabo G, Gelonch J. [Tumor markers and gastric cancer. TAG-72 is the most useful]. Med Clin (Barc) 1998;111:800. [Spanish].

Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito MR, Casale V, Pericoli MN, Vecchione A, Casciani CU, Greiner JW, Schlom J.

Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay. Cancer Res 1996;56:5293-5298.

Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Arcuri R, Carlini S, Mariotti S, Gandolfo GM, Casciani CU, Greiner JW, Schlom J. TAG-72 expression and its role in the biological evaluation of human colorectal cancer. Anticancer Res 1996;16(4B):2141-2148.

Hitchcock CL, Arnold MW, Young DC, Schneebaum S, Martin EW Jr. TAG-72 expression in lymph nodes and RIGS. Dis Colon Rectum 1996;39:473-475.

Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol 1995;153:1575-1579.

Myers RB, Schlom J, Srivastava S, Grizzle WE. Expression of tumor-associated glycoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Mod Pathol 1995;8:260-265.

Chung JK, Lee MC, Chung HK, Lim SM, Jang JJ, Koh CS. Concentration and distribution of tumor associated antigens TAG-72 and CEA in stomach cancer. Ann Nucl Med 1995;9:7-13.

Myers RB, Meredith RF, Schlom J, LoBuglio AF, Bueschen AJ, Wheeler RH, Stockard CR, Grizzle WE. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J Urol 1994;152:243-246.

Roa RA, Hruban RH, McKenzie P, Richtsmeier W. Tumor-associated glycoprotein expression in salivary gland mucoepidermoid carcinomas: an immunohistochemical study using the monoclonal antibody B72.3. Laryngoscope 1994;104(3 Pt 1):304-308.

Cavaliere F, Guadagni F, D’Agnano I, Casaldi V, Sciarretta F, Spila A, Cosimelli M. Biologic and clinical correlations among ploidy, cell kinetics, and the tumor-associated glycoprotein-72 tissue expression in colorectal cancer. Preliminary findings. Dis Colon Rectum 1994;37(2 Suppl):S24-S29.

Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, Abbolito MR, Greiner JW, Schlom J. Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, Part I. Dis Colon Rectum 1994;37(2 Suppl):S16-S23.

Hackett TE, Kaminski P, Olt GJ, Zaino R, Podczaski E. Tissue distribution of TAG-72 in malignant mixed müllerian tumors of the uterus. Gynecol Oncol 1994;52:165-171.

Contegiacomo A, Alimandi M, Muraro R, Pizzi C, Calderopoli R, De Marchis L, Sgambato A, Pettinato G, Petrella G, De Filippo MR, et al. Expression of epitopes of the tumour-associated glycoprotein 72 and clinicopathological correlations in mammary carcinomas. Eur J Cancer 1994;30A(6):813-820.

Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol 1993;48:148-154.

Sirgi KE, Wick MR, Swanson PE. B72.3 and CD34 immunoreactivity in malignant epithelioid soft tissue tumors. Adjuncts in the recognition of endothelial neoplasms. Am J Surg Pathol 1993;17:179-185.

Kuroki M, Fernsten PD, Wunderlich D, Colcher D, Simpson JF, Poole DJ, Schlom J. Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. Cancer Res 1990;50:4872-4879.

Katari RS, Fernsten PD, Schlom J. Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. Cancer Res 1990;50:4885-4890.

Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 1988;48:6811-6818.

Takasaki H, Tempero MA, Uchida E, Büchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J, Pour PM. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. Int J Cancer 1988;42:681-686.

Ohuchi N, Simpson JF, Colcher D, Schlom J. Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int J Cancer 1987;40:726-733.

Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850-857.

Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986;76:995-1006.

Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118-3124.

Lottich SC, Johnston WW, Szpak CA, Delong ER, Thor A, Schlom J. Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. Breast Cancer Res Treat 1985;6:49-56.

Horan Hand P, Colcher D, Salomon D, Ridge J, Noguchi P, Schlom J. Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. Cancer Res 1985;45:833-840.

Nuti M, Teramoto YA, Mariani-Costantini R, Hand PH, Colcher D, Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 1982;29:539-545.[/expand]
 

Structural, functional, and pharmacokinetic properties of anti-TAG-72 antibodies

[expand title=”Click to Expand”]Yu Y, Fang L, Sun D. Biodistribution of HuCC49∆CH2-β-galactosidase in colorectal cancer xenograft model. Int J Pharm 2010;386:208-215.

Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW Jr, Sun D. Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 2007;47:227-237.

Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G. Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother Radiopharm 2006;21:106-116.

Xiao J, Horst S, Hinkle G, Cao X, Kocak E, Fang J, Young D, Khazaeli M, Agnese D, Sun D, Martin E Jr. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm 2005;20:16-26.

Larson SB, Day JS, Glaser S, Braslawsky G, McPherson A. The structure of an antitumor C(H)2-domain-deleted humanized antibody. J Mol Biol 2005;348:1177-1190.

Glaser SM, Hughes IE, Hopp JR, Hathaway K, Perret D, Reff ME. Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies. J Biol Chem 2005;280:41494-41503.

Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003;18:751-759.

Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol Immunol 2003;40:337-349.

De Pascalis R, Gonzales NR, Padlan EA, Schuck P, Batra SK, Schlom J, Kashmiri SV. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. Clin Cancer Res 2003;9:5521-5531.

Kashmiri SV, Iwahashi M, Tamura M, Padlan EA, Milenic DE, Schlom J. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Crit Rev Oncol Hematol 2001;38:3-16.

Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 1997;12:305-316.

Triozzi PL, Kim JA, Martin EW Jr, Colcher D, Heffelfinger M, Rucker R. Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal cancer. Hybridoma 1997;16:147-151.

Roberson PL, Dudek S, Buchsbaum DJ. Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. Cancer 1997;80(12 Suppl):2567-2575.

Cook CH, Hinkle GH, Thurston MO, Martin EW Jr. Pharmacokinetics of iodine-125 CC49 monoclonal antibody in patients with colon cancer. Cancer Biother Radiopharm 1996;11:415-422.

Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 1995;14:461-473.

Slavin-Chiorini DC, Kashmiri SV, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, Hand PH. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;55(23 Suppl):5957s-5967s.

Gallinger S, Reilly RM, Kirsh JC, Odze RD, Schmocker BJ, Hay K, Polihronis J, Damani MT, Shpitz B, Stern HS. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 1993;53:271-278.

Slavin-Chiorini DC, Horan Hand PH, Kashmiri SV, Calvo B, Zaremba S, Schlom J. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int J Cancer 1993;53:97-103.

Stern H, Reilly R, Gallinger S, Kirsh J, DeAngelis C, Papa M, Hay K, Polihronis J, Schmoker B. Radioimmunodetection of colorectal cancer metastases with 131I-labeled monoclonal antibody B72.3: a pilot study to determine efficacy of detection and pharmacokinetics. Cancer Invest 1993;11:129-134.

Calvo B, Kashmiri SV, Hutzell P, Hand PH, Slavin-Chiorini DC, Schlom J, Zaremba S. Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody. Cancer Biother 1993;8:95-109.

Brandwein MS, Huvos AG, Patil J, Jagirdar J. Tumor-associated glycoprotein distribution detected by monoclonal antibody B72.3 in salivary neoplasia. Cancer 1992;69:2623-2630.

Webster WB, Harwood SJ, Carroll RG, Morrissey MA. Pharmacokinetics of indium-111-labeled B72.3 monoclonal antibody in colorectal cancer patients. J Nucl Med 1992;33:498-504.

Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, Hinkle G, Siler K. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992;52:1067-1072.

Meredith RF, Khazaeli MB, Plott WE, Saleh MN, Liu T, Allen LF, Russell CD, Orr RA, Colcher D, Schlom J, Shochat D, Wheeler RH, LoBuglio AF. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992;33:23-29.

Colcher DM, Milenic DE, Schlom J. Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies. Targeted Diagn Ther 1992;6:23-44.

Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K, Colcher D, Schlom J, Shochat D, LoBuglio AFR. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991;51:5461-5466.

Cajigas HE, Fariza E, Scully RE, Thor AD. Enhancement of tumor-associated glycoprotein-72 antigen expression in hormone-related ovarian serous borderline tumors. Cancer 1991;68:348-354.

Rosenblum MG, Kavanagh JJ, Burke TW, Wharton JT, Cunningham JE, Shanken LJ, Silva EG, Thompson L, Cheung L, Lamki L, Murray JL. Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst 1991;83:1629-1636

Schlom J, Hand PH, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, Reynolds JC, Larson SM, Raubitschek A. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res 1990;50(3 Suppl):820s-827s.

Schlom J, Siler K, Colcher D, Carrasquillo JA, Reynolds JC, Sugarbaker P, Larson SM. Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview. Acta Radiol Suppl 1990;374:123-128.

Colcher D, Milenic DE, Ferroni P, Carrasquillo JA, Reynolds JC, Roselli M, Larson M and Schlom J. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med 1990;3:1133-1142.

Battista P, Muraro R, Mammarella S, Curia MC, Colasante A, Rosini S, Lesti G, Sacco R, French D, Frati L, Costantini RM. Complementary reactivities of anti-carcinoembryonic antigen and antitumor-associated glycoprotein 72 monoclonal antibodies in lung carcinomas. Cancer Res 1990;50:6987-6994.

Molinolo A, Simpson JF, Thor A, Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 1990;50:1291-1298.

Colcher D, Milenic D, Roselli M, Raubitschek A, Yarranton G, King D, Adair J, Whittle N, Bodmer M, Schlom J. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res 1989;49:1738-1745.

Schlom J, Colcher D, Roselli M, Carrasquillo JA, Reynolds JC, Larson SM, Sugarbaker P, Tuttle SE, Martin EW. Tumor targeting with monoclonal antibody B72.3. Int J Rad Appl Instrum B 1989;16:137-142.

Schlom J, Colcher D, Szpak CA, Johnston WW, Sugarbaker P, Carrasquillo JA, Reynolds JC, Larson SM. A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors. Prog Clin Biol Res 1989;288:63-72

Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW, Simpson JF, Molinolo A, Noguchi P, Schlom J. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988;48:4588-4596.

Esteban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, Reynolds JC, Larson SM, Schlom J. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987;39:50-59.

Colcher D, Esteban JM, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987;47:1185-1189.

Colcher D, Carrasquillo JA, Esteban JM, Sugarbaker P, Reynolds JC, Siler K, Bryant G, Larson SM, Schlom J. Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients. Int J Rad Appl Instrum B 1987;14:251-262.

Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987;47:4218-4224.

Colcher D, Keenan AM, Larson SM, Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 1984;44:5744-5749.[/expand]
 

Tumor/tissue binding of anti-TAG-72 antibodies

[expand title=”Click to Expand”]Nawgiri RS, Nagle JA, Wilbur DC, Pitman MB. Cytomorphology and B72.3 labeling of benign and malignant ductal epithelium in pancreatic lesions compared to gastrointestinal epithelium. Diagn Cytopathol 2007;35:300-305.

Epivatianos A, Poulopoulos A, Kayavis I, Papanayotou P. Tumor-associated glycoprotein 72 (TAG-72) expression in salivary gland neoplasia: an immunohistochemical study using the monoclonal antibody (MAb) CC49. Oral Dis 2000;6:112-117.

Saleh MN, Tilden AB, Meredith RF, LoBuglio AF, Grizzle WE. Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy. Biotech Histochem 1998;73:186-197.

Mangili F, Sassi I, Di Rocco M, Leone BE, Garancini P, Santambrogio G. Breast carcinoma detection with a combination of radiolabeled monoclonal antibodies. Promising results from immunohistochemistry studies. Cancer 1996;78:2334-2339.

Kairemo KJ, Jekunen AP, Bondestam S, Korppi-Tommola ET, Savolainen S, Paavonen T. Detection of pseudomyxoma peritonei by radioimmunohistochemistry and radioimmunoscintigraphy. Cancer Biother Radiopharm 1996;11:325-334.

Roselli M, Hitchcock CL, Molinolo A, Milenic DE, Colcher D, Martin EW Jr, Hinkle GH, Schlom J. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients. Anticancer Res 1995;15:975-984.

Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol 1995;153:1575-1579.

Roa RA, Hruban RH, McKenzie P, Richtsmeier W. Tumor-associated glycoprotein expression in salivary gland mucoepidermoid carcinomas: an immunohistochemical study using the monoclonal antibody B72.3. Laryngoscope 1994;104(3 Pt 1):304-308.

Loy TS, Nashelsky MB. Reactivity of B72.3 with adenocarcinomas. An immunohistochemical study of 476 cases. Cancer 1993;72:2495-2498.

Brandwein MS, Huvos AG, Patil J, Jagirdar J. Tumor-associated glycoprotein distribution detected by monoclonal antibody B72.3 in salivary neoplasia. Cancer 1992;69:2623-2630.

Muraro R, Frati L, Bei R, Ficari F, Valli C, French D, Mammarella S, Caramia F, Fegiz G, Mariani-Costantini R. Regional heterogeneity and complementation in the expression of the tumor-associated glycoprotein 72 epitopes in colorectal cancer. Cancer Res 1991;51:5378-5383.

Molinolo A, Simpson JF, Thor A, Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 1990;50:1291-1298.

Thor A, Viglione MJ, Muraro R, Ohuchi N, Schlom J, Gorstein F. Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues. Int J Gynecol Pathol 1987;6:235-247.

Ohuchi N, Simpson JF, Colcher D, Schlom J. Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int J Cancer 1987;40:726-733.

Esteban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, Reynolds JC, Larson SM, Schlom J. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987;39:50-59.

Colcher D, Esteban JM, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987;47:1185-1189.

Colcher D, Carrasquillo JA, Esteban JM, Sugarbaker P, Reynolds JC, Siler K, Bryant G, Larson SM, Schlom J. Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients. Int J Rad Appl Instrum B 1987;14:251-262.

Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986,76:995-1006.

Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850-857.

Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986;76:995-1006.

Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118-3124.

Lottich SC, Johnston WW, Szpak CA, Delong ER, Thor A, Schlom J. Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. Breast Cancer Res Treat 1985;6:49-56.

Stramignoni D, Bowen R, Atkinson BF, Schlom J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 1983;31:543-552.

Nuti M, Teramoto YA, Mariani-Costantini R, Hand PH, Colcher D, Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 1982;29:539-545.

Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199-3203.[/expand]
 

Imaging with anti-TAG-72 antibodies

[expand title=”Click to Expand”]Xu JS, Huang J, Qin R, Hinkle GH, Povoski SP, Martin EW, Xu RX. Synthesizing and binding dual-mode poly (lactic-co-glycolic acid) (PLGA) nanobubbles for cancer targeting and imaging. Biomaterials 2010;31:1716-1722.

Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW Jr, Subramaniam V, Xu R, Sun D. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 2009;6:428-440.

Hladik P, Vizda J, Bedrna J, Simkovic D, Strnad L, Smejkal K, Voboril Z. Immunoscintigraphy and intra-operative radioimmunodetection in the treatment of colorectal carcinoma. Colorectal Dis 2001;3:380-386.

Blend MJ, Bhadkamkar VA. Impact of radioimmunoscintigraphy on the management of colorectal and ovarian cancer patients: a retrospective study. Cancer Invest 1998;16:431-441.

Di Carlo V, De Nardi P, Stella M, Magnani P, Fazio F. Preoperative and intraoperative radioimmunodetection of cancer pretargeted by biotinylated monoclonal antibodies. Semin Surg Oncol 1998;15:235-238.

Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 1997;38:512-516.

Kairemo KJ, Jekunen AP, Bondestam S, Korppi-Tommola ET, Savolainen S, Paavonen T. Detection of pseudomyxoma peritonei by radioimmunohistochemistry and radioimmunoscintigraphy. Cancer Biother Radiopharm 1996;11:325-334.

Method MW, Serafini AN, Averette HE, Rodriguez M, Penalver MA, Sevin BU. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report. Cancer 1996;77:2286-2293.

Kairemo KJ, Jekunen AP, Bondestam S, Korppi-Tommola ET, Savolainen S, Paavonen T. Detection of pseudomyxoma peritonei by radioimmunohistochemistry and radioimmunoscintigraphy. Cancer Biother Radiopharm 1996;11:325-334.

Mörschel M, Bockisch A, Junginger T. [Immunoscintigraphy with MAb B72.3 for preoperative detection of lymph node metastases of colorectal carcinoma]. Chirurg 1995;66:503-506. [German].

Scott AM, Macapinlac HA, Divgi CR, Zhang JJ, Kalaigian H, Pentlow K, Hilton S, Graham MC, Sgouros G, Pelizzari C, Chen G, Schlom J, Goldsmith SJ, Larson SM. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 1994;35:1976-1984.

Divgi CR, Scott AM, McDermott K, Fallone PS, Hilton S, Siler K, Carmichael N, Daghighian F, Finn RD, Cohen AM, Schlom J, Larson SM. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nucl Med Biol 1994;21:9-15.

Kostakoglu L, Divgi CR, Hilton S, Cordon-Cardo C, Scott AM, Kalaigian H, Finn RD, Schlom J, Larson SM. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. Cancer Invest 1994;12:551-558.

Stern H, Reilly R, Gallinger S, Kirsh J, DeAngelis C, Papa M, Hay K, Polihronis J, Schmoker B. Radioimmunodetection of colorectal cancer metastases with 131I-labeled monoclonal antibody B72.3: a pilot study to determine efficacy of detection and pharmacokinetics. Cancer Invest 1993;11:129-134.

Muxí A, Pons F, Herranz R, Novell F, Fernández R, Filella X, García A, Solá M, Trías M, Setoain J. Radioimmunoscintigraphy of colorectal carcinoma with a 111In-labelled anti-TAG-72 monoclonal antibody. Nucl Med Commun 1993;14:775-787.

Gallinger S, Reilly RM, Kirsh JC, Odze RD, Schmocker BJ, Hay K, Polihronis J, Damani MT, Shpitz B, Stern HS. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 1993;53:271-278.

Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates. Cancer 1993;72(11 Suppl):3453-3462.

Stern H, Reilly R, Gallinger S, Kirsh J, DeAngelis C, Papa M, Hay K, Polihronis J, Schmoker B. Radioimmunodetection of colorectal cancer metastases with 131I-labeled monoclonal antibody B72.3: a pilot study to determine efficacy of detection and pharmacokinetics. Cancer Invest 1993;11:129-134.

Collier BD, Abdel-Nabi H, Doerr RJ, Harwood SJ, Olsen J, Kaplan EH, Winzelberg GG, Grossman SJ, Krag DN, Mitchell EP. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992;185:179-186.

Winzelberg GG, Grossman SJ, Rizk S, Joyce JM, Hill JB, Atkinson DP, Sudina K, Anderson K, McElwain D, Jones AM. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response. Cancer 1992;69:1656-1663.

Carrasquillo JA. Imaging of colorectal carcinoma with 131I B72.3 monoclonal antibody. Targeted Diagn Ther 1992;6:45-55.

Sergile SL, Haller DG, Daly JM. Use of radiolabelled monoclonal antibodies in patients with primary and metastatic large bowel cancer. Surg Oncol 1992;1:391-398.

Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 1991;32:1326-1332.

Vijayakumar V, Blend MJ, Johnson D, Schnobrich K, Golick J. Detection of recurrent colon cancer with In-111 labeled MoAb B72.3 in a patient with normal CEA and TAG-72 levels. Clin Nucl Med 1992;17:180-184.

Lange MK, Martin EW Jr. Monoclonal antibodies in imaging and therapy of colorectal cancer. World J Surg 1991;15:617-622.

Schlom J, Siler K, Colcher D, Carrasquillo JA, Reynolds JC, Sugarbaker P, Larson SM. Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview. Acta Radiol Suppl 1990;374:123-128.

Doerr RJ, Abdel-Nabi H, Baker JM, Steinberg S. Detection of primary colorectal cancer with indium 111 monoclonal antibody B72.3. Arch Surg 1990;125:1601-1605.

Abdel-Nabi H, Doerr RJ, Chan HW, Balu D, Schmelter RF, Maguire RT. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. Radiology 1990;175:163-171.

Carrasquillo JA, Sugarbaker P, Colcher D, Reynolds JC, Esteban J, Bryant G, Keenan AM, Perentesis P, Yokoyama K, Simpson DE, Ferroni P, Farkas R, Schlom J, Larson SM. Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. J Nucl Med 1988;29:1022-1030.

Lastoria S, D’Amico P, Mansi L, Giordano GG, Rossiello R, Schlom J, Pace E, Panza N, Pacilio G, Salvatore M. A prospective imaging study of 131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: preliminary report. Nucl Med Commun 1988;9:347-356

Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988:48:4597-4603.

Esteban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, Reynolds JC, Larson SM, Schlom J. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987;39:50-59.

Colcher D, Esteban JM, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987;47:1185-1189.

Colcher D, Carrasquillo JA, Esteban JM, Sugarbaker P, Reynolds JC, Siler K, Bryant G, Larson SM, Schlom J. Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients. Int J Rad Appl Instrum B 1987;14:251-262.

Lundy J, Mornex F, Keenan AM, Greiner JW, Colcher D. Radioimmunodetection of human colon carcinoma xenografts in visceral organs of congenitally athymic mice. Cancer 1986;57:503-509.

Colcher D, Keenan AM, Larson SM, Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 1984;44(12 Pt 1):5744-5751.

Keenan AM, Colcher D, Larson SM, Schlom J. Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3.J Nucl Med 1984;25:1197-1203.[/expand]
 

Intraoperative detection with anti-TAG-72 antibodies

[expand title=”Click to Expand”]Agnese DM, Abdessalam SF, Burak WE, Arnold MW, Soble D, Hinkle GH, Young D, Kazaeli MB, Martin EW Jr. Pilot study using a humanized CC49 monoclonal antibody (HuCC49∆CH2) to localize recurrent colorectal carcinoma. Ann Surg Oncol 2004;11:197-202.

Schneebaum S, Troitsa A, Haddad R, Avital S, Kashtan H, Baratz M, Brazovsky E, Papo J, Skornick Y. Immunoguided lymph node dissection in colorectal cancer: a new challenge? World J Surg 2001;25:1495-1498;discussion 1499.

Haddad R, Avital S, Troitsa A, Chen J, Baratz M, Brazovsky E, Gitstein G, Kashtan H, Skornick Y, Schneebaum S. Benefits of radioimmunoguided surgery for pelvic recurrence. Eur J Surg Oncol 2001;27:298-301.

Hladik P, Vizda J, Bedrna J, Simkovic D, Strnad L, Smejkal K, Voboril Z. Immunoscintigraphy and intra-operative radioimmunodetection in the treatment of colorectal carcinoma. Colorectal Dis 2001;3:380-386.

Avital S, Haddad R, Troitsa A, Kashtan H, Brazovsky E, Gitstein G, Skornick Y, Schneebaum S. Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation. Cancer 2000;89:1692-1698.

Schneebaum S, Troitsa A, Avital S, Haddad R, Kashtan H, Gitstein G, Baratz M, Brazovsky E, Papo J, Skornick Y. Identification of lymph node metastases in recurrent colorectal cancer. Recent Results Cancer Res 2000;157:281-292.

Muxi A, Pons F, Vidal-Sicart S, Setoain FJ, Herranz R, Novell F, Fernandez RM, Trias M, Setoain J. Radioimmunoguided surgery of colorectal carcinoma with an 111In-labelled anti-TAG72 monoclonal antibody. Nucl Med Commun 1999;20:123-130.

Arnold MW, Young DM, Hitchcock CL, Barberá-Guillem E, Nieroda C, Martin EW Jr. Staging of colorectal cancer: biology vs. morphology. Dis Colon Rectum 1998;41:1482-1487

Barbera-Guillem E, Arnold MW, Nelson MB, Martin EW Jr. First results for resetting the antitumor immune response by immune corrective surgery in colon cancer. Am J Surg 1998;176:339-343.

Bakalakos EA, Young DC, Martin EW Jr. Radioimmunoguided surgery for patients with liver metastases secondary to colorectal cancer. Ann Surg Oncol 1998;5:590-594.

Avital S, Hitchcock CL, Baratz M, Haddad R, Skornick Y, Schneebaum S. Localization of monoclonal antibody CC49 in colonic metastasis from renal cell carcinoma. Eur J Surg Oncol 1998;24:149-151.

Mussa A, Sandrucci S, Mobiglia A, Baccega M, Mussa B, De Filippi PG. Role of radioimmunolocalization in the staging of gastric carcinoma. Semin Surg Oncol 1998;15:209-211.

Lucisano E, Bertoglio S. Role of radioimmunoguided surgery using iodine-125-labeled B72.3 monoclonal antibody in gastric cancer surgery. Semin Surg Oncol 1998;15:212-214.

Grazia M, Bini A, Stella F, Pagani D, Bazzocchi R. Radioimmunoguided surgery and intraoperative lung cancer staging. Semin Surg Oncol 1998;15:215-219.

Renda A, Iovino F, Capasso L, Ricciardelli L, Tammaro V, Acampa W. Radioimmunoguided surgery in colorectal cancer: a 6-year experience with four different technical solutions. Semin Surg Oncol 1998;15:226-230.

Percivale P, Bertoglio S, Meszaros P, Schenone F, Gipponi M, Moresco L, Cosso M, Badellino F. Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer. Semin Surg Oncol 1998;15:231-234.

Badellino F, Bertoglio S, Mariani G, Meszaros P, Canavese G, Percivale P. Use of radioimmunoguided surgery after induction chemotherapy in locally advanced breast cancer. Semin Surg Oncol 1998;15:245-248.

Bertoglio S, Percivale P, Schenone F, Peressini A, Murolo C, Badellino F. Role of tumor-associated antigen expression in radioimmunoguided surgery for colorectal and breast cancer. Semin Surg Oncol 1998;15:249-253.

Bertoglio S, Benevento A, Percivale P, Cafiero F, Moresco L, Peressini A, Dionigi R, Badellino F. Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer. Semin Surg Oncol 1998;15:263-267.

Di Carlo V, De Nardi P, Stella M, Magnani P, Fazio F. Preoperative and intraoperative radioimmunodetection of cancer pretargeted by biotinylated monoclonal antibodies. Semin Surg Oncol 1998;15:235-238.

Mansi L, Di Lieto E, Rambaldi PF, Bergaminelli C, Fallanca F, Vicidomini G, Cuccurullo V, Mancusi R. [Preliminary experience with radioimmuno-guided surgery of primary neoplasms of the lung]. Minerva Chir 1998;53:369-372. [Italian].

LaValle GJ, Martinez DA, Sobel D, DeYoung B, Martin EW Jr. Assessment of disseminated pancreatic cancer: a comparison of traditional exploratory laparotomy and radioimmunoguided surgery. Surgery 1997;122:867-871;discussion 871-873.

McIntosh DG, Colcher D, Seemayer T, Smith ML. The intraoperative detection of ovarian adenocarcinoma using radiolabeled CC49 monoclonal antibody and a hand-held gamma-detecting probe. Cancer Biother Radiopharm 1997;12:287-294.

Manayan RC, Hart MJ, Friend WG. Radioimmunoguided surgery for colorectal cancer. Am J Surg 1997;173:386-389.

Bertsch DJ, Burak WE Jr, Young DC, Arnold MW, Martin EW Jr. Radioimmunoguided surgery for colorectal cancer. Ann Surg Oncol 1996;3:310-316.

Martin EW Jr, Thurston MO. The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection. Cancer Invest 1996;14:560-571.

Cote RJ, Houchens DP, Hitchcock CL, Saad AD, Nines RG, Greenson JK, Schneebaum S, Arnold MW, Martin EW Jr. Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49. Cancer 1996;77:613-620.

Percivale P, Bertoglio S, Meszaros P, Canavese G, Cafiero F, Gipponi M, Campora E, Gasco M, Badellino F. Radioimmunoguided surgery after primary treatment of locally advanced breast cancer. J Clin Oncol 1996;14:1599-1603.

Arnold MW, Hitchcock CL, Young DC, Burak WE Jr, Bertsch DJ, Martin EW Jr. Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radioimmunoguided surgery. Dis Colon Rectum 1996;39:509-513.

Arnold MW, Young DC, Hitchcock CL, Schneebaum S, Martin EW Jr. Radioimmunoguided surgery in primary colorectal carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging. Am J Surg 1995;170:315-318.

Bertsch DJ, Burak WE, Young DC, Arnold MW, Martin EW Jr. Radioimmunoguided surgery improves survival for patients recurrent colorectal cancer. Surgery 1995;118:634-638;discussion 638-639.

Schneebaum S, Arnold MW, Houchens DP, Greenson JK, Cote RJ, Hitchcock CL, Young DC, Mojzisik CM, Martin EW Jr. The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 1995;75:2809-2817.

Burak WE Jr, Schneebaum S, Kim JA, Arnold MW, Hinkle G, Berens A, Mojzisik C, Martin EW Jr. Pilot study evaluating the intraoperative localization of radiolabeled monoclonal antibody CC83 in patients with metastatic colorectal carcinoma. Surgery 1995;118:103-108.

Di Carlo V, Stella M, De Nardi P, Fazio F. Radioimmunoguided surgery: clinical experience with different monoclonal antibodies and methods. Tumori 1995;81(3 Suppl):98-102.

Mörschel M, Bockisch A, Junginger T. [Immunoscintigraphy with MAb B72.3 for preoperative detection of lymph node metastases of colorectal carcinoma]. Chirurg 1995;66:503-506. [German].

Di Carlo V, Badellino F, Stella M, De Nardi P, Fazio F, Percivale P, Bertoglio S, Schenone F, Benevento A, Carcano G, et al. Role of B72.3 iodine 125-labeled monoclonal antibody in colorectal cancer detection by radioimmunoguided surgery. Surgery 1994;115:190-198.

Stella M, De Nardi P, Paganelli G, Magnani P, Mangili F, Sassi I, Baratti D, Gini P, Zito F, Cristallo M, Fazio F, Di Carlo V. Avidin-biotin system in radioimmunoguided surgery for colorectal cancer. Advantages and limits. Dis Colon Rectum 1994;37:335-343.

Paganelli G, Stella M, Zito F, Magnani P, De Nardi P, Mangili F, Baratti D, Veglia F, Di Carlo V, Siccardi AG, Fazio F. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. J Nucl Med 1994;35:1970-1975.

Badalament RA, Burgers JK, Petty LR, Mojzisik CM, Berens A, Marsh W, Hinkle GH, Martin EW Jr. Radioimmunoguided radical prostatectomy and lymphadenectomy. Cancer 1993;71:2268-2275.

Kim JA, Triozzi PL, Martin EW Jr. Radioimmunoguided surgery for colorectal cancer. Oncology (Williston Park) 1993;7:55-60;discussion 60, 63-64.

Arnold MW, Schneebaum S, Berens A, Petty L, Mojzisik C, Hinkle G, Martin EW Jr. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg 1992;216:627-632.

Arnold MW, Schneebaum S, Berens A, Mojzisik C, Hinkle G, Martin EW Jr. Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 1992;112:624-629;discussion 629-630.

Collier BD, Abdel-Nabi H, Doerr RJ, Harwood SJ, Olsen J, Kaplan EH, Winzelberg GG, Grossman SJ, Krag DN, Mitchell EP. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992;185:179-186.

Krag DN, Haseman MK, Ford P, Smith L, Taylor MH, Schneider P, Goodnight JE. Gamma probe location of 111indium-labeled B72.3: an extension of immunoscintigraphy. J Surg Oncol 1992;51:226-230.

Sergile SL, Haller DG, Daly JM. Use of radiolabelled monoclonal antibodies in patients with primary and metastatic large bowel cancer. Surg Oncol 1992;1:391-398.

Quinlan D, Davidson A, Gamponia E, Lindley J, Doshi H. Detection of tumor-associated glycoprotein-72 (TAG-72) in short-term and long-term surviving colon cancer patients using a first- and second-generation monoclonal antibody. Proc Am Assoc Cancer Res 1991;32:271.

Martin EW Jr, Carey LC. Second-look surgery for colorectal cancer. The second time around. Ann Surg 1991;214: 321-325; discussion 326-327.

Cohen AM, Martin EW Jr, Lavery I, Daly J, Sardi A, Aitken D, Bland K, Mojzisik C, Hinkle G. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 1991;126:349-352.

Stella M, De Nardi P, Paganelli G, Sassi I, Zito M, Magnani P, Baratti D, Mangili F, Spagnolo W, Siccardi AG, et al. Surgery for colorectal cancer guided by radiodetecting probe. Clinical evaluation using monoclonal antibody B72.3. Eur J Surg 1991;157:485-488.

Del Vecchio S, Camera L, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M. Clinical studies with B72.3 in ovarian cancer and probe-guided tumor localization. Int J Rad Appl Instrum B 1991;18:85-87.

Lange MK, Martin EW Jr. Monoclonal antibodies in imaging and therapy of colorectal cancer. World J Surg 1991;15:617-622.

Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW Jr. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect Prev 1991;15:225-229.

Nieroda CA, Mojzisik C, Sardi A, Ferrara P, Hinkle G, Thurston MO, Martin EW Jr. Radioimmunoguided surgery in primary colon cancer. Cancer Detect Prev 1990;14:651-656.

Martin EW Jr, Hinkle G, Mojzisik C, Thurston MO. Radioimmunoguided surgery: a new intraoperative approach to the detection of tumor. Cancer Treat Res 1990;51:387-411.

Bell J, Mojzisik C, Hinkle G Jr, Derman H, Schlom J, Martin E. Intraoperative radioimmunodetection of ovarian cancer using monoclonal antibody B72.3 and a portable gamma-detecting probe. Obstet Gynecol 1990;76:607-611.

Sampsel JW, Hinkle G, Nieroda C, Ignaszewski J, Thurston M, Martin EW. Gamma-detecting probe and autoradiographic studies of radiolabeled antibody B72.3 in CX-1 colon xenografts. J Surg Oncol 1990;45:242-249.

Sardi A, Siddiqi MA, Hinkle GH, Rousseau M, Gersman M, Hill T, Olsen J, Tuttle SE, Young D, Houchens D, Thurston M, Martin EW Jr. Localization by hand-held gamma probe of tumor labeled with antibody “cocktail”. J Surg Res 1989;47:227-234.

Nieroda CA, Mojzisik C, Sardi A, Farrar WB, Hinkle G, Siddiqi MA, Ferrara PJ, James A, Schlom J, Thurston MO, Martin EW. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. Surg Gynecol Obstet 1989;169:35-40.

Martin EW Jr, Mojzisik CM, Hinkle GH, Sampsel J, Siddiqi M, Tuttle SE, Sickle-Santanello B, Colcher D, Thurston MO, Bell J, Farrar WB, Schlom J. Radioimmunoguided surgery using monoclonal antibody. Am J Surg 1988;156:386-392.

Tuttle SE, Jewell SD, Mojzisik CM, Hinkle GH, Colcher D, Schlom J, Martin EW Jr. 1988. Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and MAb B72.3: comparison of in vivo gamma probe counts with in vitro MAb radiolocalization. Int J Cancer 1988; 42:352-358.

Sickle-Santanello BJ, O’Dwyer PJ, Mojzisik C, Tuttle SE, Hinkle GH, Rousseau M, Schlom J, Colcher D, Thurston MO, Nieroda C, Sardi A, Farrar WB, Minton JP, Martin EW Jr. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum 1987;30:761-764.[/expand]
 

Other targeted therapies with anti-TAG-72 antibodies

[expand title=”Click to Expand”]Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging 2009, Dec 15. [Epub ahead of print].

Fang L, Sun D. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. Drug Metab Dispos 2008;36:1153-1165.

Kim KS, Lee YK, Kim JS, Koo KH, Hong HJ, Park YS. Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes. Cancer Gene Ther 2008;15:331-340.

Fang L, Battisti RF, Cheng H, Reigan P, Xin Y, Shen J, Ross D, Chan KK, Martin EW Jr, Wang PG, Sun D. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J Med Chem 2006;49:6290-6297.

Mohsin H, Jia F, Sivaguru G, Hudson MJ, Shelton TD, Hoffman TJ, Cutler CS, Ketring AR, Athey PS, Simón J, Frank RK, Jurisson SS, Lewis MR. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu. Bioconjug Chem 2006;17:485-492.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother Radiopharm 2005; 20:502-513.

Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm 2005;20:467-478.

Meredith R, Shen S, Macey D, Khazaeli MB, Carey D, Robert F, LoBuglio A. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm 2003;18:393-404.

Graves SS, Dearstyne E, Lin Y, Zuo Y, Sanderson J, Schultz J, Pantalias A, Gray D, Axworthy D, Jones HM, Auditore-Hargreaves K. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 2003;9(10 Pt 1):3712-3721.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2002;8:2806-2811.

Kennel SJ, Brechbiel MW, Milenic DE, Schlom J, Mirzadeh S. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49. Cancer Biother Radiopharm 2002;17:219-231.

Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM Jr, Kilgore LC, Grizzle WE, Schlom J, LoBuglio AF. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 2001;16:305-315.

Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 2000;6:3095-3102.

Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 2000;11:258-266.

Laitinen JO, Tenhunen M, Kairemo KJ. Absorbed dose estimates for 131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma. Nucl Med Commun 2000;21:355-360.

Domingo RJ, Reilly RM. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin. Nucl Med Commun 2000;21:89-96.

Kim JA, Bresler HS, Martin, EW Jr., Aldrich W, Heffelfinger M, Triozzi PL. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer 1999;86:22-36.

Nag S, Martinez-Monge R, Nieroda C, Martin E Jr. Radioimmunoguided-intraoperative radiation therapy in colorectal carcinoma: a new technique to precisely define the clinical target volume. Int J Radiat Oncol Biol Phys 1999;44:133-137.

Meredith RF, Khazaeli MB, Macey DJ, Grizzle WE, Mayo M, Schlom J, Russell CD, LoBuglio AF. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999;5(10 Suppl):3254s-3258s.

Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 1999;5:953-961.

Rucker R, Bresler HS, Heffelfinger M, Kim JA, Martin EW Jr, Triozzi PL. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer. J Immunother 1999;22:80-84.

Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 1997;15:1518-1528.

Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD, Wheeler RH, Liu T, Grizzle WE, Schlom J, LoBuglio AF. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 1996;37:1491-1496.

Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L, Schlom J, Larson SM. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995;36:586-592.

Divgi CR, Scott AM, Gulec S, Broussard EK, Levy N, Young C, Capitelli P, Daghighian F, Williams JM, Finn RD, Kemeny N, Hilton S, Kelsen D, Milenic DE, Lora ME, Schlom J, Larson SM. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma. Clin Cancer Res 1995;1:1503-1510.

Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995;1:1447-1454.

Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-1022.

Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG, Podoloff DA. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer 1994;73(3 Suppl):1057-1066.

Triozzi PL, Kim JA, Aldrich W, Young DC, Sampsel JW, Martin EW Jr. Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody. Cancer 1994;73:580-589.

Rosenblum MG, Kavanagh JJ, Burke TW, Wharton JT, Cunningham JE, Shanken LJ, Silva EG, Thompson L, Cheung L, Lamki L, et al. Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst 1991;83:1629-1636.

Camera L, Del Vecchio S, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M. Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma. Eur J Nucl Med 1991;18:269-273.

Del Vecchio S, Mansi L, Petrillo A, Camera L, Sofia M, Marra A, Carratù L, Salvatore M. Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer. Eur J Nucl Med 1991;18:129-132.

Lange MK, Martin EW Jr. Monoclonal antibodies in imaging and therapy of colorectal cancer. World J Surg 1991;15:617-622.

Simonson RB, Ultee ME, Hauler JA, Alvarez VL. Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody. Cancer Res 1990;50(3 Suppl):985s-988s.

Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987;47:4218-4224.[/expand]
 

Reviews on intraoperative detection of cancer

[expand title=”Click to Expand”]Povoski SP, Neff RL, Mojzisik CM, O’Malley DM, Hinkle GH, Hall NC, Murrey DA Jr, Knopp MV, Martin EW Jr. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol 2009;7:11.

Sun D, Bloomston M, Hinkle G, Al-Saif OH, Hall NC, Povoski SP, Arnold MW, Martin EW. Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future. J Surg Oncol 2007;96:297-308.

Martin EW Jr, Thurston MO. Intraoperative radioimmunodetection. Semin Surg Oncol 1998;15:205-208.

Martinez DA, Barbera-Guillem E, LaValle GJ, Martin EW Jr. Radioimmunoguided Surgery for Gastrointestinal Malignancies: An Analysis of 14 Years of Clinical Experience. Cancer Control 1997;4:505-516.[/expand]
 

Integrated imaging technologies in oncology

[expand title=”Click to Expand”]Hall NC, Zhang J, Povoski SP, Martin EW, Knopp MV: New developments in imaging and functional biomarker technology for the assessment and management of cancer patients. Expert Rev Med Devices, 2009;6:347-351.

Hall NC, Povoski SP, Murrey DA Jr, Knopp MV, Martin EW Jr. Bringing advanced medical imaging into the operative arena could revolutionize the surgical care of cancer patients. Expert Rev Med Devices 2008;5:663-667.[/expand]
 

Other antibody-guided technologies

[expand title=”Click to Expand”]Bahnson EE, Murrey DA, Mojzisik CM, Hall NC, Martinez-Suarez HJ, Knopp MV, Martin EW, Povoski SP, Bahnson RR. PET/CT Imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody. Ther Adv Uro 2009;1:67-70.

Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wüest T, Stenner F, Perani A, Cohen L, Knuth A, Divgi C, Jäger D, Scott AM, Ritter G, Old LJ, Renner C. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer 2009;125:115-123.

Strong VE, Humm J, Russo P, Jungbluth A, Wong WD, Daghighian F, Old L, Fong Y, Larson SM: A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes. Surg Endosc 2008;22:386-391.

Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007;8:279-281[/expand]